Acutaas Chemicals Ltd Share Price

Overview

Acutaas Chemicals Ltd share price is currently ₹3,224.39, down by - ₹37.28 (1.14%) from its previous closing price of ₹3,261.67. The share price has declined -0.62% over the past month and gained 132.69% over the past year. The stock's 52-week low and high are ₹1,282.06 and ₹3,698.48, respectively. Acutaas Chemicals Ltd has a market capitalisation of ₹ 25,950.00 Cr. The share price was last updated on 26 Aug 2026, 03:57 PM IST.

Acutaas Chemicals Ltd
Acutaas Chemicals Ltd
ACUTAAS
 0.00
- 37.28
1.14%
Healthcare
 0.00(%)1D

Updated: 26 Aug 2026, 03:57:23 pm IST

Market Data

Open Price

 3,267.81

Prev. Close

 3,261.67
 3,199.64

Day Low

 3,307.32

Day High

 1,282.06

52 Week Low

 3,698.48

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

68.36

Sector PE

42.03

PB Ratio

20.16

Sector PB

5.83

EPS

47.17

Dividend Yield

0.06

Today's Volume

144.022 K

5 Day Avg. Volume

282.538 K

PEG Ratio

1.02

Market Cap.

₹ 25,950.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 30% at ₹1.5/Share
18-Sep-202518-Sep-2025
Stock Split5:10
25-Apr-202525-Apr-2025
DividendsFinal Dividend of 30% at ₹3/Share
13-Sep-202413-Sep-2024

Mutual Fund Ownership

Mutual Fund Holder
Jun 26
Shares held
Jul 26
Shares held
Motilal Oswal Flexi Cap Fund - Regular Plan - Growth5.24 Lac
10.86 Lac
(107.16%)
SBI Healthcare Opportunities Fund - Regular Plan - IDCW9.00 Lac
9.00 Lac
no change
Kotak Multicap Fund - Regular Plan - Growth12.16 Lac
8.27 Lac
(32%)
SBI Large & Midcap Fund - Regular Plan - IDCW4.70 Lac
4.70 Lac
no change
Kotak Multi Asset Allocation Fund - Regular Plan - Growth4.53 Lac
4.53 Lac
no change

About Acutaas Chemicals Ltd 👋

Acutaas Chemicals Limited, formerly Ami Organics Limited, is an India-based company, which is engaged in the manufacturing of pharma intermediates and specialty chemicals. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. It manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It has developed and commercialized over 610 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Neha

Neha

21 Aug • 10:19 AM · SEBI-Registered Analyst

Stocks With Strong Future Guidance — Worth Tracking

• V-Marc • RR Kabel • Finolex • HFCL

HFCL
• E2E Networks • MTAR Technologies • Syrma SGS • Netweb Technologies • Sterlite Technologies • Sansera Engineering • Azad Engineering • Omnitech Engineering • Dynamatic Technologies • Aequs • Rossell Techsys • Sona BLW • TD Power Systems • Ramkrishna Forgings • Happy Forgings • Shivalik Bimetal Controls • KSH International • Gland Pharma • Aarti Pharmalabs • Kwality Pharmaceuticals • Sudeep Pharma • Hitachi Energy India • Neogen Chemicals • Quality Power • Ather Energy • Sky Gold • Cupid • Sai Life Sciences • Electronics Mart India • Neuland Laboratories • Shilpa Medicare • Laurus Labs • Shadowfax Technologies • Sedemac Mechatronics • Siemens Energy India • Premier Energies • Navin Fluorine • Mold-Tek Technologies • Muthoot Microfinance • SJS Enterprises • Lloyds Engineering Works • Garware Hi-Tech Films • Universal Cables • Kalyan Jewellers • Bluestone Jewellery • P N Gadgil & Sons • TVS Motor • Bajaj Auto • Paytm • Eternal • IDFC First Bank • PNGS Reva Diamond Jewellery • Craftsman Automation • Apcotex Industries • Timex Group India • Deep Industries • Cholamandalam Investment & Finance • Equitas Small Finance Bank • Acutaas Chemicals • Apar Industries • CreditAccess Grameen • Lodha Developers • Shriram Finance • Sakar Healthcare • Rajratan Global Wire • Fineotex Chemical • Thyrocare Technologies • Ujjivan Small Finance Bank • Emmvee Photovoltaic Power • Gandhar Oil Refinery • NTPC Green Energy • Titan Company • Cyient DLM • Polycab India • Hindusthan Urban Infrastructure • Mahindra & Mahindra Financial Services • Huhtamaki India • Adani Energy Solutions • Dynamic Cables • Beta Drugs • Shyam Metalics & Energy • Anand Rathi Wealth • Prime Cable Industries • Groww • Landmark Cars • ICICI Bank • Bhansali Engineering Polymers • Poonawalla Fincorp • Jayaswal Neco Industries • Tatva Chintan Pharma Chem • Navkar Corporation • Federal Bank • Jio Financial Services • RBL Bank • L&T Finance • V2 Retail • SG Finserve

See More
Stock Reader

Stock Reader

19 Aug • 6:43 AM · SEBI-Registered Analyst

Acutaas Chemicals (ACUTAAS) Business & Investment Outlook

ACUTAAS
Acutaas Chemicals delivered strong Q1 FY27 growth, supported by advanced intermediates, improving margins and growing opportunities across pharmaceuticals, semiconductor materials and battery chemicals. Strengths Strong Q1 performance: Revenue increased 59% YoY, EBITDA 122% and PAT 68%. Advanced Intermediates: Revenue grew 77% YoY to around ₹290 crore. Diversified business: Exposure to pharmaceutical intermediates, specialty chemicals and semiconductor materials. Margin expansion: Product mix and operating leverage are supporting profitability. Weaknesses Specialty Chemicals pressure: Revenue declined 11% YoY as the company phases out lower-margin commodity chemicals. Quarterly volatility: Q1 is seasonally weaker, making quarterly comparisons less representative of the full year. Execution requirements: Multiple new businesses require successful commissioning and ramp-up. Opportunities Semiconductor growth: Strong demand from AI and memory chips could support the company's BFC business. Indichem facility: The new manufacturing facility is expected to start contributing from Q1 FY28. Battery chemicals: Trial runs have been completed and the plant is moving toward commissioning. Pharma opportunity: Healthy RFP activity across NCE and API provides potential for future growth. Threats Execution risk in new facilities and product launches. Cyclicality in semiconductor and specialty chemical markets. Customer concentration or project delays could affect growth. Valuation risk: Strong earnings expectations may already be reflected in the stock price. Key Takeaway Acutaas Chemicals is transitioning toward higher-value specialty and advanced chemical products, while expanding into semiconductor and battery chemicals. The key factors to monitor are revenue growth, EBITDA margins, advanced-intermediate demand, Indichem commissioning, battery-chemical ramp-up and cash-flow generation.

See More
Kumar Satyam

Kumar Satyam

18 Aug • 8:37 PM · SEBI-Registered Analyst

Acutaas Chemicals Receives ECMS Approval for Electrolyte Additives

Key Highlights Acutaas Chemicals has received approval under the Electronics Components Manufacturing Scheme (ECMS) for its electrolyte additives business. The approval supports the company's expansion plans, with an expected incentive benefit of up to 25% during FY31. Business Update • Cumulative Investment: ₹256.47 Crore. • Eligible Investment: ₹119.12 Crore. • Expected Incentive Benefit: Up to 25% during FY31. • The approval supports expansion of the company's electrolyte additives business. What It Means • ECMS approval supports the company's investment and expansion plans in electrolyte additives. • The eligible investment of ₹119.12 Crore forms the basis for the expected scheme benefits. • The potential incentive of up to 25% during FY31 could support the economics of the planned investment. • Expansion in electrolyte additives provides an opportunity to increase the company's presence in the electronics components manufacturing ecosystem. Market Impact Impact: Positive The ECMS approval is a positive development for Acutaas Chemicals, as it supports the company's electrolyte additives expansion and provides eligibility for incentives. The potential benefit of up to 25% during FY31 adds to the strategic significance of the approval. Learning Outcome The Electronics Components Manufacturing Scheme (ECMS) is a government framework designed to support domestic manufacturing of electronics components. Incentive schemes can improve the economics of eligible investments and encourage companies to expand local manufacturing capabilities.

ACUTAAS

See More
Ankit Gupta

Ankit Gupta

18 Aug • 1:19 PM · SEBI-Registered Analyst

ACUTAAS
CHEMICALS

ACUTAAS
: APPROVAL RECEIVED UNDER ELECTRONICS COMPONENTS MANUFACTURING SCHEME FOR ELECTROLYTE ADDITIVES BUSINESS; CUMULATIVE INVESTMENT OF ₹256.47 CRORES WITH ELIGIBLE INVESTMENT OF ₹119.12 CRORES; EXPECTED INCENTIVE BENEFIT UP TO 25% DURING FY 2030-31.

See More
Pankaj pawar

Pankaj pawar

18 Aug • 11:59 AM · SEBI-Registered Analyst

ACUTAAS

**ECMS Approval & Incentive Benefit** **

ACUTAAS
:** Received approval under the **Electronics Components Manufacturing Scheme (ECMS)** for its **electrolyte additives business**. The company has made cumulative investments of **₹256.47 crore**, including **₹119.12 crore of eligible investment**, with an incentive benefit of up to **25%** expected through FY31. **Impact:** **Positive;** the incentive support can reduce effective project costs and strengthen the company's electrolyte additives expansion and long-term growth outlook.

See More
Shrikant Pandey

Shrikant Pandey

18 Aug • 11:39 AM · SEBI-Registered Analyst

ACUTAAS CHEMICALS ; GETS APPROVAL UNDER ELECTRONICS COMPONENTS

ACUTAAS CHEMICALS ; GETS APPROVAL UNDER ELECTRONICS COMPONENTS MANUFACTURING SCHEME 🧪

ACUTAAS
✅ Acutaas Chemicals has received approval for an incentive package under the Electronics Components Manufacturing Scheme (ECMS) for its Electrolyte Additives manufacturing business. 💰 Company proposes a cumulative investment of ₹256.47 Cr, of which ₹119.12 Cr is eligible investment under the scheme. 📈 Company is expected to receive an incentive benefit of up to 25% of the eligible investment, subject to fulfilment of applicable terms and conditions. 🏭 Approval supports Acutaas Chemicals’ expansion in the electronics components manufacturing ecosystem. ⏳ Incentive period is 5 years from January 27, 2026. 🟢 Impact: Positive — government incentive support can lower effective project costs and support expansion of the Electrolyte Additives business.

See More

News & Events

Frequently Asked Questions

What is the share price of Acutaas Chemicals Ltd?

What is the market cap of Acutaas Chemicals Ltd?

Should I buy Acutaas Chemicals Ltd stock now?

What is the 52 week high and low of Acutaas Chemicals Ltd?

Is the Acutaas Chemicals Ltd stock good to buy?

Is Acutaas Chemicals Ltd a good buy for the long term?

Is Acutaas Chemicals Ltd overvalued or undervalued?

What is the PE and PB ratio of Acutaas Chemicals Ltd?

Start Now